2843 E. Grand River Avenue – #230 East Lansing, MI 48823 [email protected] 303-783-0924

Research Articles


Ongoing Research

Research Articles – Updates

September 2016

  • The BMC ( British Journal of Cancer) features an article on molecular classification of uterine leiomyosarcomas. Their data supports the existence of distinct leiomyosarcoma subgroups which are clinically associated with tumor grades. These findings will help advance the classification of leiomyosarcomas and promote more individualized treatments. Click here for the abstract.

July 2016

  • A study exploring chromosomal abnormalities in uterine smooth muscle tumors found that uterine leiomyomas with abnormal nuclei and leiomyosarcomas are closely related. Click here for the abstract.

May 2016

  • A study published by the BJC found that antiapoptotic (anti-cell death) Bc1-2 family proteins are highly expressed in soft tissue leiomyosarcomas and inhibition of these proteins increase tumor sensitivity to chemotherapy. Click here for the abstract.

January 2016

December 2015

  • https://clinicaltrials.gov/ct2/show/NCT02180867
    • Radiation therapy with or without combination chemotherapy or Pazopanib Hydrochloride before surgery in treating patients with soft tissue sarcomas that can be removed by surgery.
  • Anti-PD1 Antibody Pembrolizumab (MK-3475) –  KEYTRUDA
    • The Sarcoma Alliance for Research through Collaboration (SARC) entered into a Phase II study of Keytruda with Merck Pharmaceutical Company, in collaboration with Dohme Corp., for advanced sarcomas, bone sarcomas, and soft tissue sarcomas – including leiomyosarcoma.
    • The study continues with no further recruitment of participants at this time.  The estimated completion date for final data collection for “primary outcome” measure is December 2016.
  • The clinical, research and social value of autopsy after any cancer death: A perspective from the Childrens Oncology Group Soft Tissue Sarcoma Committee

November 2015

October 2015

  • Yondelis (Trabectedin) Approved by the FDA for Leiomyosarcoma and Liposarcoma.
    • The chemotherapy drug Trabectedin (Yondelis) was approved by the FDA to treat Leiomyosarcoma and Liposarcoma,  deemed unresectable, yet previously treated with chemotherapy that contained the drug anthracycline.
    • Yondelis was evaluated in clinical studies involving 518 patients.  Those that were given Yondelis had a cancer progression that stopped for an average of 4.2 months, compared to an average of 1.5 months for the patient group who took another anti-cancer drug.
    • The most common side effects of Yondelis include nausea, fatigue, vomiting, diarrhea, constipation, loss of appetite, shortness of breath, headache, and tissue swelling.  The drug’s label has an additional list of side effects as well.    Yondelis is marketed by Janssen Products.